Clinical trials · Pennsylvania
Neoplasms clinical trials in Pennsylvania
We’re tracking 130 recruiting neoplasms studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Philadelphia, PennsylvaniaAges 12–85 - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Scranton, PennsylvaniaAges 18 years+ - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05235165RecruitingPhase 3
Surgery choice for lung spread of osteosarcoma
This Phase 3 trial compares two ways to remove lung metastases (open surgery vs keyhole surgery) in people with osteosarcoma. It aims to see which approach works better and is safer for patients with a limited number of lung spots that can be removed.
Allentown, PennsylvaniaAges Up to 50 years - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Philadelphia, PennsylvaniaAges birth–38 years - NCT06218628RecruitingPhase 1
Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06261814RecruitingPhase 2
Ultrasound to check chemoembolization for liver tumors
This trial uses a special ultrasound with a contrast agent to see how well a liver cancer treatment called TACE is working. It may help doctors better understand if the treatment is shrinking the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06311578RecruitingPhase 1
Study of JNJ-87704916 alone or with other drugs for advanced solid tumors
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06486454Recruiting
Liver tumor treatment with sound waves
This trial tests a new device that uses sound waves to destroy liver tumors without cutting or needles. It may be an option if you have a liver tumor that can be partly or fully targeted by this technique.
Allentown, PennsylvaniaAges 22 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Horsham, PennsylvaniaAges 18 years+ - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Penn Wynne, PennsylvaniaAges 18 years+ - NCT06782581Recruiting
Cancer Support Study for Asian Americans and Their Caregivers
This study explores how relationships and support can help Asian American cancer patients and their caregivers. You and a caregiver would join a program to improve communication and coping during cancer treatment.
Philadelphia, PennsylvaniaAges 21–80 - NCT06807437RecruitingPhase 3
Testing lanreotide before pancreas surgery to prevent leaks
This trial tests if a medicine called lanreotide, given before surgery, can prevent a common complication (pancreatic leak) after removing part of the pancreas. It is for people with pancreatic cancer or a growth that could become cancer who are scheduled for a specific type of pancreas surgery.
Bethlehem, PennsylvaniaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Doylestown, PennsylvaniaAges 18 years+ - NCT07001592RecruitingPhase 1
Injection of a modified virus for advanced GI and peritoneal cancers
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18–69 - NCT07054723Recruiting
Surviving daily life after breast cancer
This study looks at how breast cancer survivors manage daily life. Researchers want to learn from people who are 40 or older and at least 5 years past their diagnosis. The goal is to better understand what helps people thrive after cancer.
Philadelphia, PennsylvaniaAges 40 years+ - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07234968Recruiting
Stent vs no stent after bladder removal surgery
This study looks at whether leaving a small tube (ureteral stent) in place after bladder removal helps recovery. It compares people who get a stent to those who don't, focusing on problems like leaks or infections after surgery.
Philadelphia, PennsylvaniaAges 18–85
Neoplasms trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting neoplasms studies listed above.
- Thomas Jefferson University Hospital · 7 studies
- Fox Chase Cancer Center · 4 studies
- Alliance Cancer Specialists · 2 studies
- Geisinger Medical Center · 2 studies
- Geisinger Wyoming Valley/Henry Cancer Center · 2 studies
- GSK Investigational Site · 2 studies
- Lehigh Valley Hospital-Cedar Crest · 2 studies
- University of Pennsylvania · 2 studies
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Neoplasms trials in other states
Common questions
- Are there neoplasms clinical trials in Pennsylvania?
- Yes. We're currently tracking 130 recruiting neoplasms studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.